trending Market Intelligence /marketintelligence/en/news-insights/trending/TfuSD8XJsP7LDvqvPWN4JQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Lexicon Pharmaceuticals Inc.'s investigational, oral diabetes drug sotagliflozin met its primary endpoint in a phase 3 clinical trial.

The company was studying the treatment in type 1 diabetes patients who were on insulin therapy. The study met its primary endpoint after demonstrating superiority over placebo and a well-tolerated safety profile during a 24-week treatment period.

Results from the study will be submitted for publication in a peer-reviewed journal.

The drug is also being studied in adults with type 2 diabetes.